From CNBC: The FDA approved the new drug from Biogen, priced at $56,000 per year, despite a near-unanimous "no" vote from a key advisory committee.
From MedPage Today: A newly approved 'medication' for 'schizophrenia' and 'bipolar disorder' promises to reduce usual weight gain with olanzapine (Zyprexa) by making it less pleasant to eat food.
From Change.org: The mental health system in Trieste, Italy, which for decades has been widely recognized as a model for good community care, is under threat of being dismantled by a new political faction.
From Medium: What Americans really need is to fix the cycles of abuse that have driven them to seek, and yet never find, safety in the unsafe world they have created.
From The Telegraph: A coroner ruled that Margaret Molyneux, 69, died of natural causes, but a review found that she had been prescribed higher than recommended doses of the drug olanzapine (Zyprexa).
From Antidepressant Risks: Katinka Blackford Newman, Professor David Healey, Sarah Culshaw and Dr. Ed White have teamed up on a new website helping people understand the risks of taking antidepressants.
From Psychiatric Times: "If such a willingness to discount the feelings and testimonies [of patients] is widespread, I cannot help but think that psychiatry is really in a serious [moral] crisis."
From RxISK: Leemon McHenry reviews the first novel published by David Healy's writers co-operative—"a must-read for medical professionals, and especially aspiring key opinion leaders."
From the Disability Visibility Project: Those of us who have survived psychiatric incarceration know that not only did the asylum never die — it is, and always was, another prison.
From the World Health Organization: Many mental health services around the world are failing people. There is a different path that countries and services can take.
From Motherly: A number of recent studies highlight the relationship between parental affection and children’s happiness and success.
From ISPS-US: A review of the science that calls for a radical change or evidence-based paradigm shift in psychiatric care, and pilot projects that tell of a new way.
From ProPublica: An investigation found repeated breakdowns in oversight as states failed to protect young people in need of specialized care.
From Pacific Standard: Children in ABA programs learn that body is not their own, the way they move is wrong, and there is no neutral way for them to naturally exist in the world.
From Fox News: The Cornell family alleged that prescribed medication, especially lorazepam (Ativan), led to erratic behavior from the Soundgarden frontman before his death by suicide.
From eMHIC: The time for change is upon us. Mental health services should focus on the human-to-human relationship as the primary mechanism of healing.
Barbara Ehrenreich weighs in on mass-market mindfulness, Silicon Valley, Buddhism- sliced up and commodified.
From The Guardian: Such symptoms occur in half of patients, and the correct response is to taper off their medication more slowly, says Dr Mark Horowitz.
From lonerwolf: There are two main types of spiritual emergency: mystical psychosis (hallucinations, mania, etc.) and the dark night of the soul (depression).
From Fugitive Psychiatrist: "I can’t believe I have patients walking around on 800mg of this stuff. There’s no way in good conscience I could dose this BID (sic) unless a patient consented to 20 hours of sleep a day."
From The Wall Street Journal: Psychiatric hospitals kept their accreditation after patients said they were raped or assaulted; died by suicide; slept on chairs due to crowding; and more.
Collective Evolution discusses a recent commentary by the editor of The Lancet stating that "much of the scientific literature, perhaps half, may simply be untrue."
From Mindfreedom: Please help us protect 22-year-old Charles Helmer by taking one or more actions before Friday!
From NBC News: The ban should have meant victory for those fighting the school, but more than a year later, it hasn't actually changed anything.
From UCL Beacon Bursary fund: This event aims to explore the lived-experience perspective when attempting to distinguish withdrawal effects from relapse.